How brain areas for speech and hearing work after cerebellar stroke
Studies how the brain hears and controls speech in adults with cerebellar stroke.
Plain-language title generated from the registry record
Registry title: Imaging Speech in Neurotypical Adults and Individuals With Cerebellar Stroke
Key facts
- Where
- Pittsburgh, United StatesSee the site
Where in United States
- University of PittsburghPittsburgh, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Pittsburgh
- Trial code
- NCT06458153
- Record updated
- 18 June 2026
- Original description
The goal of this research study is to learn how the brain areas that plan and control movement interact with the areas responsible for hearing and perceiving speech in healthy adults and people who have had cerebellar strokes. The main questions it aims to answer are:Read full original descriptionShow less
High-resolution Functional Imaging of Speech-induced Sensory Modulation
The goal of this research study is to learn how the brain areas that plan and control movement interact with the areas responsible for hearing and perceiving speech in healthy adults and people who have had cerebellar strokes. The main questions it aims to answer are:
1. What regions of the brain's sensory systems show changes in their activity related to speech? 2. To what extent do these regions help listeners detect and correct speech errors? 3. What is the role of the cerebellum (a part of the brain in the back of the head) in these activities?
Participants will be asked to complete several experimental sessions involving behavioral speech and related tests and non-invasive brain imaging using electroencephalography (EEG) and functional magnetic resonance imaging (fMRI).
Inclusion: Cohort 1 (neurotypical adults):; Age 18-49; Right-handed; Native English speaker; Cohort 2 (people with cerebellar lesions):; Age 18 or older; Right-handed; Native English speaker; History of cerebellar stroke; Cohort 3 (controls matched to Cohort 2); Age 18 or older; Right-handed; Native English speaker.
Exclusion: Presence of MRI risk factors: metal and/or electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant; Presence of MRI risk factors: metal and/or electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant; Presence of MRI risk factors: metal and/or electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant; History of neurological / neurodegenerative disease or severe brain injury (e.g., stroke or severe traumatic brain injury); Clinical diagnosis and/or treatment for schizophrenia or other psychotic disorders; Clinical diagnosis and/or treatment for neurocognitive disorders (e.g., dementia, delirium); Presence of a severe and unmanaged, clinically diagnosed attention disorder; Clinically diagnosed with or treated for a speech, language, or hearing disorder; History of severe claustrophobia; History of neurological / neurodegenerative disease or severe brain injury other than stroke; Clinical diagnosis and/or treatment for schizophrenia or other psychotic disorders; Clinical diagnosis and/or treatment for neurocognitive disorders (e.g., dementia, delirium); Presence of a severe and unmanaged, clinically diagnosed attention disorder; History of severe claustrophobia; History of neurological / neurodegenerative disease or severe brain injury (e.g., stroke or severe traumatic brain injury); Clinical diagnosis and/or treatment for schizophrenia or other psychotic disorders; Clinical diagnosis and/or treatment for neurocognitive disorders (e.g., dementia, delirium); Presence of a severe and unmanaged, clinically diagnosed attention disorder; Clinically diagnosed with or treated for a speech, language, or hearing disorder; History of severe claustrophobia; Cohort 1 (neurotypical adults):; Hearing loss, defined by pure tone thresholds >25 decibels (dB) hearing level (HL) at octave frequencies between 250-8000 Hz; Head circumference greater than 60cm or weight greater than 300 pounds; Currently pregnant; Cohort 2 (people with cerebellar lesions):; Hearing loss, defined by pure tone thresholds >50 dB HL at octave frequencies between 250-4000 Hz; Head circumference greater than 60cm or weight greater than 300 pounds; Currently pregnant; Cohort 3 (controls matched to Cohort 2):; Hearing loss, defined by pure tone thresholds >50 dB HL at octave frequencies between 250-4000 Hz; Head circumference greater than 60cm or weight greater than 300 pounds; Currently pregnant.